SLC7A3 and osteosarcoma: Targeting SLC7A3 to inhibit arginine uptake is suggested as a potential therapeutic strategy, especially in the context of osteosarcoma, as SLC7A3 facilitates arginine uptake, which in turn could promote tumor growth and metastasis [38, 42].